Stock & Company Details
Kymera Therapeutics Inc $KYMR
Price:
N/A
N/A
83M
$9.1B
52 Week High:
N/A
10 Day Average Volume:
N/A
-33.72
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
KYMR technical indicators
Latest Kymera Therapeutics Inc (KYMR) indicator readings as of 2026-10-09.
KYMR's 14-day RSI is 49.2, in neutral territory. At $112.40 it is trading 20.0% above its 200-day moving average of $93.69, and below its 50-day average of $114.61. Price sits in the middle of its Bollinger Bands ($104.94 to $121.16). ADX reads 13.4, indicating a range-bound market rather than a trend.
KYMR backtested strategy results
How 4 rule-based strategies performed on Kymera Therapeutics Inc (KYMR) over recent history, last backtested 2026-09-05. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | -4.9% | 25% | 16 | -76.7% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +212.6% | 33% | 30 | -65.2% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +81.4% | 40% | 30 | -54.5% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | -18.2% | 39% | 28 | -66.6% |
Overview
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Finance Bot
Ask your questions
Start by typing a question below.
